RE:CG Oncology NMIBC data We are beating CG0070 so far it seems. They are at 27-28% CR as single agent and many more treatments. We are so far 28% plus 10% PR. They are the second best after us. Of course combination drugs are expected to do better Dr Kamat had once suggested that we would be combined with a checkpoint inhibitor as well. I expect we hit the same numbers or better once we combo for nonresponders. IMHO
Donein25 wrote: ScieneFirst. What are we to make of their CG0070? They have released inpressive CRs in small (32 pt.) partnered combo with Keytruda for NMIBC. They are a small private biotech but already have partnered up on combos with BMS Opdivo and Roche Tecentriq. I'd like to see us making deals like this sooner rather than later. Do you see us as more attractive to future partners, when we get to that point in time?.